Seretide Inhaler 25 mikrograma + 250 mikrograma u jednoj dozi stlačeni inhalat, suspenzija
Name | Seretide Inhaler 25 mikrograma + 250 mikrograma u jednoj dozi stlačeni inhalat, suspenzija |
---|---|
Marketing Authorisation Number | HR-H-572113579 |
Active Substance | salmeterolksinafoat flutikazonpropionat |
Composition | jedna inhalacijska doza sadržava 25 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata |
Pharmaceutical Form | stlačeni inhalat, suspenzija |
Manufacturer | Glaxo Wellcome Production, Evreux, Francuska Glaxo Wellcome S.A., Aranda de Duero, Burgos, Španjolska |
Marketing Authorisation Holder | GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska |
Marketing Authorisation Date | 20.08.2021 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/14-02/30 |
Registration Number | 381-12-01/70-21-28 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | R03AK06 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |